SacredBod's longer take on Propionyl L-Carnitine — context the structured blocks above don't capture.
L-carnitine bound to propionic acid. Different from base L-carnitine (general energy) and acetyl-L-carnitine (brain-targeted, ALCAR). The propionyl group provides additional substrate for the TCA cycle and shows more affinity for cardiac and vascular tissues.
Like other carnitines, transports long-chain fatty acids into mitochondria for beta-oxidation. The propionyl moiety enters the TCA cycle directly via propionyl-CoA → succinyl-CoA. The vascular preference may explain peripheral artery disease (PAD) walking distance improvements seen in trials.
The evidence base (B- grade) reflects this: Moderate evidence in PAD walking distance. Cardiovascular benefit better-supported than performance/longevity claims. For practical use, the typical dose range is 500 mg 2-3 times daily for vascular indications, ideally with a fat-containing meal for fat-soluble compounds.
Who benefits most: Adults with PAD or intermittent claudication, congestive heart failure patients, men with vascular-origin erectile dysfunction (combination with sildenafil shown synergistic in small trials).
Cautions: End-stage kidney disease (carnitine clearance issues). Concurrent thyroid hormone supplementation (potential interaction). Pregnancy without medical oversight.
Pairing notes: Ubiquinol for cardiac energy support. L-arginine for vascular function.